Vis enkel innførsel

dc.contributor.authorAaseth, Jan
dc.contributor.authorRootwelt, Helge
dc.contributor.authorRetterstøl, Kjetil
dc.contributor.authorHestad, Knut
dc.contributor.authorFarup, Per Grønaas
dc.coverage.spatialNorwayen_US
dc.date.accessioned2023-01-27T09:47:00Z
dc.date.available2023-01-27T09:47:00Z
dc.date.created2022-09-12T09:37:10Z
dc.date.issued2022
dc.identifier.citationNutrients. 2022, 14 (12), .en_US
dc.identifier.issn2072-6643
dc.identifier.urihttps://hdl.handle.net/11250/3046791
dc.description.abstractThe efficacy of various bariatric procedures on the mitigation of the obese dyslipidemia remains debated, and the impact of these measures on lipoprotein(a) (Lp(a)) levels is unknown. In this study we aimed to compare the two most commonly used procedures: gastric bypass (RYGB) and sleeve gastrectomy (SG). Adult patients with morbid obesity were assigned to receive either RYGB or SG. The levels of non-HDL cholesterol, LDL/HDL-ratio and Lp(a) at examinations conducted 6 and 12 months postoperatively were determined and compared to preoperative levels to estimate the efficacy of the two surgical methods. All results 6 and 12 months after surgery were used in the comparisons with the preoperative results. A linear mixed regression model for repeated analyses was used. The Lp(a) and the non-HDL cholesterol levels were considerably reduced in the RYGB group, in contrast to the minor changes in the SG group. In addition, the LDL/HDL ratio was significantly more reduced in the RYGB group when compared to the SG group. Conclusively, RYGB was found to be more efficient than SG for the mitigation of obese dyslipidemia, including preoperative high Lp(a)-levels. This might have important individual and societal implications, especially regarding the potential to reduce the risk of cardiovascular disease and the related societal costs.en_US
dc.description.sponsorshipThe work was funded from Innlandet Hospital Trust, Brumunddal, Norwayen_US
dc.language.isoengen_US
dc.rightsNavngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/deed.no*
dc.subjectHDLen_US
dc.subjectLDLen_US
dc.subjectcholesterolen_US
dc.subjectdyslipidemiaen_US
dc.subjectgastric bypassen_US
dc.subjectgastric sleeveen_US
dc.subjectlipoprotein(a)en_US
dc.subjectmorbid obesityen_US
dc.titleCirculating Lipoproteins in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomyen_US
dc.title.alternativeCirculating Lipoproteins in Subjects with Morbid Obesity Undergoing Bariatric Surgery with Gastric Bypass or Sleeve Gastrectomyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).en_US
dc.subject.nsiovervekten_US
dc.subject.nsivektreduksjonen_US
dc.subject.nsigastroenterologien_US
dc.subject.nsisykelig overvekten_US
dc.subject.nsicomorbiditeten_US
dc.subject.nsimagetarm funksjonenen_US
dc.subject.nsikirurgisk operasjonen_US
dc.subject.nsibio-psyko-sosiale faktoreren_US
dc.source.pagenumber8en_US
dc.source.volume14en_US
dc.source.journalNutrientsen_US
dc.source.issue12en_US
dc.identifier.doi10.3390/nu14122381
dc.identifier.cristin2050601
dc.source.articlenumber2381en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal